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Between the Bazaar and the Bench: 
Making of the Drugs Trade in Colonial 
India, ca. 1900–1930
nandini bhattacharya
Summary: This article analyzes why adulteration became a key trope of the Indian 
drug market. Adulteration had a pervasive presence, being present in medical 
discourses, public opinion and debate, and the nationalist claim for government 
intervention. The article first situates the roots of adulteration in the composite 
nature of this market, which involved the availability of drugs of different poten-
cies as well as the presence of multiple layers of manufacturers, agents, and dis-
tributors. It then shows that such a market witnessed the availability of drugs of 
diverse potency and strengths, which were understood as elements of adulteration 
in contemporary medical and official discourse. Although contemporary critics 
argued that the lack of government legislation and control allowed adulteration 
to sustain itself, this article establishes that the culture of the dispensation of drugs 
in India necessarily involved a multitude of manufacturer–retailers, bazaar trad-
ers, and medical professionals practicing a range of therapies.
Keywords: drugs trade, Ayurveda, bazaar medicine, adulteration, colonial India, 
medical market, Drugs Enquiry Committee, indigenous drugs
At the turn of the nineteenth century colonial India was awash with pat-
ent and proprietary medicines, tinctures, tonics, powders, and tabloids 
of every description. Many were imported from Great Britain or the 
United States; a substantial number also arrived from Germany, France, 
Italy, and the fast-industrializing Japan. These were sold by British Indian 
agents in India, who also traded in compounds and galenicals that they 
manufactured themselves. They competed with Indian druggists, who 
were large-scale importers and also did extensive business with fledgling 
Indian firms in the early twentieth century. Therapeutic and cosmetic 
I wish to thank the Wellcome Trust, which funded the research for this article. I am 
grateful to the staff of the APAC, British Library, Wellcome Library, Baroda Record Office 
Vadodara, and National Library, Calcutta, for all their help in the course of my research.
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products of varying standards and efficacy were sold directly to consum-
ers by small merchants, itinerant traders, and Ayurvedic and Hakimi 
practitioners as well.
This article argues that the prevailing distinctions drawn between 
indigenous and Western drugs in colonial India are misleading. These 
distinctions are premised on an understanding of cultural nationalism. 
They do not take into account the heterogeneous nature of the trade, 
manufacture, and consumption patterns in the market. An understand-
ing of this composite nature of the drug market provides a unique entry 
point to the question of adulteration of drugs within that market. The 
heterogeneity of the market did not only involve the availability and diver-
sity of drugs or the multiple layers of agents and distributors involved in 
that trade, although these were characteristic of that market. This market 
witnessed the availability of drugs of diverse potency and strengths, some-
times one single drug sold in several degrees of potency. This was as true 
of Ayurvedic and Hakimi medicines as of Western therapeutic products. 
For the latter, there was always British Pharmacopeia (BP) as the standard 
of reference, but neither the importers not local manufacturers were 
restricted by its recommendations. This diversity of drugs and potencies 
was defined within contemporary medical, official, and public discourse 
as “adulteration.” This article proposes adulteration as the key trope of 
the colonial Indian drug market.
Adulteration of drugs in this market has been almost entirely ignored 
by historians, except with reference to the distribution of quinine. Patricia 
Barton has pointed out that the colonial government’s efforts to distribute 
cheap packets of quinine throughout India failed due to flaws in distribu-
tion and the common adulteration prevalent in the use of cinchona and 
its alkaloids in India.1 While Barton has made an important contribution 
to the history of adulteration of drugs, her perspective is limited to qui-
nine. The problems of adulteration in quinine (or cinchona) cannot be 
seen in isolation to the entirety of the political and cultural complexities 
that defined the drug market in colonial India. This article explores the 
story of heterogeneity and adulteration in the emergent Indian drug 
market. It argues that the discourse of adulteration in drug production 
and marketing in India was informed by uniquely Indian realities, such 
as the share of the indigenous drugs in the market, economic national-
ism (swadeshi), the elusive allure of import substitution, and a plurality of 
medical traditions and practices. The problem of adulteration of drugs in 
India is wider than that of a lack of government regulation. This article 
1. Patricia Barton, “‘The Great Quinine Fraud’: Legality Issues in the ‘Non-Narcotic’ 
Drug Trade in British India,” Soc. Hist. Alcohol Drugs 22, no. 1 (2007): 6–25.
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explains how the drug market in colonial India was formed and why it 
remained largely uncontrolled in spite of state or nationalist intervention.
Historians of medicine have examined the histories of the pharmaceuti-
cal industries in Europe and North America, focusing on industrialization, 
collaborations between the industry and medical schools, and new market-
ing strategies in the late nineteenth and twentieth centuries.2 These stud-
ies have emphasized that organization, often into cartels (in the United 
Kingdom), and marketing strategies helped British drug companies to 
expand in the late nineteenth century, while the German industry largely 
depended on research and the production of new patents. In the United 
States, collaborations between universities and corporations helped in 
the manufacture of new drugs.3
Although scholarship in Indian history of medicine has explored how 
colonialism changed institutions and praxis of medicine in India, there 
is relatively scant attention to a history of the production and the delivery 
of drugs. Recent histories on drugs in India have focused on Ayurvedic 
and Unani therapy: their marketing, standardization, and tangled rela-
tionship with the British Indian medical establishment and with Indian 
nationalism. These narratives of the “modernization” and nationalization 
of indigenous drugs focus on the cultural nationalism, specifically in sci-
ence and medicine through an interaction of their practitioners with 
several strands of Indian nationalist activity. This provided the political 
context of the consolidation of the corporate identities of Ayurvedic and 
Unani practitioners and informed new marketing strategies, transforming 
traditional drugs into modern Ayurveda or Unani therapeutics. Ayurvedas 
and Hakims used the print media in major Indian languages of Punjabi, 
Hindi, and Urdu to sustain the discourse of the Indian body, with nation-
alist political movements in order to build the edifice for a legitimate, 
2. R. P. T. Davenport-Hines and J. Slinn, Glaxo: A History to 1962 (Cambridge: Cambridge 
University Press, 1992); Jonathan Liebenau, Medical Science and Medical Industry: The Formation 
of the American Pharmaceutical Industry (Baltimore: Johns Hopkins University Press, 1987); V. 
Quirke, Collaboration in the Pharmaceutical Industry: Changing Relationships in Britain and France, 
1935–1965 (New York: Routledge, 2008); Michael Robson, “The French Pharmaceutical 
Industry, 1919–1939,” in Pill Peddlers: Essays on the History of the Pharmaceutical Industry, ed. 
Gregory J. Higby, Elaine Stroud, and Jonathan Liebenau (Madison: American Institute of 
the History of Pharmacy, 1990), 107–21; Roy Church and E. M. Tansey, Burroughs, Wellcome 
& Co.: Knowledge, Trust, Profit and the Transformation of the British Pharmaceutical Industry, 
1880–1940 (Lancaster: Crucible, 2007).
3. Judy Slinn, “Research and Development in the UK Pharmaceutical Industry from 
the Nineteenth Century to the 1960s,” in Drugs and Narcotics in History, ed. Roy Porter and 
Mikuláš Teich (Cambridge: Cambridge University Press, 1996), 168–86.
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collective identity for themselves.4 The construction of this indigenous 
collective was not seamless; as Kavita Sivaramakrishnan has pointed out, 
the Punjabi vaids resisted the Hindi-dominated discourse that validated 
Hindu nationalism and instead opted to appropriate “indigenous” sci-
ence in Punjabi language and a Sikh solidarity.5 In the Unani tradition, 
as Seema Alavi has argued, the discourse of authentic Unani practitioners 
in the Urdu public sphere occurred in counterpoint to the rise of the self-
qualified hakim and the dissemination of Unani knowledge as well as its 
consolidation in print and practice in north India.6 In the princely court 
of Hyderabad, the practice of Unani bypassed the contentious debates 
between the reformers and traditional Unani practice was absorbed into 
an institutionalized hospital system.7
Rachel Berger has claimed that the Indigenous Drugs Committee, insti-
tuted by the government of India, privileged a few useful Indian drugs, 
but not the knowledge system of Ayurvedic medicine, which instead “pre-
sented medically useful components of Indian agriculture as something 
that Europeans had stumbled upon, of which Indians had been unaware.”8 
This is inaccurate; on the contrary, BP incorporated fifty-odd Indian drugs 
in its colonial addendum as early as in 1899.9 Instead, it is possible to argue 
that while Ayurvedic drugs were incorporated within BP, their usage by 
Western practitioners was tolerated within limits; the “bazaar medicines,” 
drugs from the local markets, were regularly used even in hospitals and 
dispensaries in British India and were “in every way efficient substitutes 
for the better known drugs of BP.”10 Projit Mukharji has shown that both 
4. See Kavita Sivaramakrishnan, Old Potions, New Bottles: Recasting Indigenous Medicine in 
Colonial Punjab, 1850–1945 (Hyderabad: Orient Longman, 2006); Madhuri Sharma, Indig-
enous and Western Medicine in Colonial India (New Delhi: Foundation Books, 2012); See also 
Charles Leslie, “The Ambiguities of Medical Revivalism in Modern India,” in Asian Medical 
Systems: A Comparative Study, ed. Charles Leslie (Berkeley: University of California Press, 
1976), 356–67.
5. Sivaramakrishnan, Old Potions, New Bottles (n. 4), 13.
6. Seema Alavi, “Unani Medicine in the Nineteenth Century Public Sphere: Urdu Texts 
and the Oudh Akhbar,” Indian Econ. Soc. Hist. Rev. 42 (2005): 101–29.
7. Guy Attewell, Refiguring Unani Tibb: Plural Healing in Late Colonial India (New Delhi: 
Orient Longman, 2007).
8. Rachel Berger, “Ayurveda and the Making of the Urban Middle Class in North India, 
1900–1945,” in Modern and Global Ayurveda: Pluralism and Paradigms, ed. Dagmar Wujastyk 
and Frederick M. Smith (Albany: State University of New York Press, 2008), 101–15.
9. GOI Medical, “GMC: A Report from the Pharmaceutical Committee on the Proposed 
Indian and Colonial Addendum to the BP of 1898” (March 1899), Asia, Pacific and Africa 
Collections, British Library (henceforth APAC), IOR/P/5645, 373–97.
10.  “The Indian and Colonial Addendum to the British Pharmacopeia,” Indian Med. 
Gazette 36 (1901): 62–63.
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Ayurveda and Hakimi in colonial India consolidated themselves through 
exclusions of subaltern knowledge and practice, and by borrowing the dis-
course of Western, scientific modernity.11 In a broader context, Mukharji 
has argued for the “vernacularization” and “provincialization” of Western 
medicine especially in Bengal as Bengali medical print in the nineteenth 
century was adapted to local medical vocabulary and praxis.12
Prior researchers have focused on Indian practitioners and the mod-
ernizing of indigenous drugs centered on the trope of indigenous medi-
cal cultures in consonance with Indian nationalism in various forms. 
Sivaramakrishnan, Berger, and Madhuri Sharma have specifically dem-
onstrated that indigenous medical theory and praxis, particularly that of 
Ayurveda, were constructed through the public sphere in Punjabi and 
Hindi in northern India.13 They have demonstrated, valuably, the work-
ings of medical science at the sites of Indian culture and politics and its 
interactions with Western medicine and colonial modernity. Their schol-
arship has provided a counterfoil to the focus by historians on the loss of 
institutional support and legitimacy of the indigenous medical systems 
in British India.14
To move from discourse to praxis, international trade in drugs and 
therapeutic products had burgeoned in the eighteenth century, commen-
surably with the volume of trade itself. With the isolation of the “active 
principles” of drugs from their raw materials, the potency of drugs for 
sale increased as well.15 As Guy Attewell has demonstrated, drugs traveled 
and were easily assimilated within different cultural traditions in the age 
of commerce, making them heterogeneous.16 Indeed, as anthropologists 
11. Projit Bihari Mukharji, “Pharmacology, ‘Indigenous Knowledge,’ Nationalism: A Few 
Words from the Epitaph of Subaltern Science,” in The Social History of Health and Medicine in 
Colonial India, ed. Biswamoy Pati and Mark Harrison (London: Routledge, 2009), 195–212.
12. Projit Bihari Mukharji, Nationalizing the Body: The Medical Market, Print and Daktari 
Medicine (London: Anthem Press, 2011), esp. 75–110.
13. Sharma, Indigenous and Western Medicine (n. 4), 120–39.
14. Deepak Kumar, “Unequal Contenders, Uneven Ground: Medical Encounters in 
British India, 1820–1920,” in Western Medicine as Contested Knowledge, ed. Andrew Cunning-
ham and Birdie Andrews (Manchester: Manchester University Press, 1997), 172–90; Neshat 
Qaiser, “Politics, Culture and Colonialism: Unani’s Debate with Doctory,” in Health, Medicine 
and Empire: Perspectives on Colonial India, ed. Biswamoy Pati and Mark Harrison (London: 
Sangam Books, 2001), 317–55.
15. Pratik Chakrabarti, “Empire and Alternatives: Swietenia febrifuga and the Cinchona 
Substitutes,” Med. Hist. 54, no. 1 (2010): 75–94.
16. Guy Attewell, “Interweaving Substance Trajectories: Tiryaq, Circulation and Therapeu-
tic Transformation in the Nineteenth Century,” in Crossing Colonial Historiographies: Histories 
of Colonial and Indigenous Medicines in Transnational Perspective, ed. Anne Digby, Waltraud 
Ernst, and Projit B. Mukharji (Newcastle upon Tyne: Cambridge Scholars Press, 2010), 1–20.
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have pointed out, even in the contemporary age of the dominance of 
biomedicine, medicines and therapeutic substances used by medical 
practitioners have remained heterogeneous, borrowed from several exist-
ing medical traditions.17 Discussions on indigenous or Indian medicine 
have therefore focused on the epistemic and discursive trajectories, with 
emphasis on cultural aspects of medicine, but have ignored the struc-
ture of the market itself. This essay asks some questions: Did nationalist 
and institutional consolidations change the content of medicines and 
therapeutic substances sold in colonial India? How were they distributed 
and marketed? Was the widespread adulteration of the market the con-
sequence of its heterogeneity? To what extent did the involvement of 
government-sponsored medical establishments that bought therapeutic 
products from the market influence the drug market?
The drugs and therapeutics trade in India was a complex one and 
occurred at multiple levels. These processes of production, marketing 
and dispensing of Indian drugs were conducted in an intensely com-
petitive, dynamic, and diverse market. The polarities of indigenous and 
Western therapeutic products were a construct of this market. The terms 
“Western” and “Indian,” “Ayurveda” and “Allopathy,” “Unani” and “Doc-
tory,” and “swadeshi” and “foreign” had deep political resonance, but 
these dialectics hardly represented the totality of the drug market and 
were reflective, often, of marketing strategies. Instead, the production 
and consumption of drugs and other therapeutic products in the late 
nineteenth- and early twentieth-century India were ideologically flexible 
and commercially vibrant. An international, heterogeneous therapeutic 
culture placed India within this trade; and this transnational commerce 
encompassed and included regional therapeutic vernaculars, both in 
medical print and therapeutic products. This market was made mostly in 
Indian cities. And although the fear of adulteration was pervasive, it was 
not a construct of the heterogeneity of the market but an inalienable part 
of the making of the market itself.
The Making of the Indian Drugs Trade
The drug market was formed through the interplay of three institutions: 
the colonial state, the emergence of the Indian middle class, and the drugs 
trade. These defined the heterogeneity of the market and led to various 
degrees of adulteration in the drug market.
17. Susan Reynolds Whyte, Sjaak Van Der Geest, and Anita Hardon, Social Lives of Medi-
cines (Cambridge: Cambridge University Press, 2002), 3–19, 79–103.
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The principal cities in colonial India were populated by a large middle 
class by the second half of the nineteenth century. These included the 
Presidency capitals of Bombay, Calcutta, and Madras as well as large pro-
vincial towns such as Delhi, Benares, Allahabad, Lahore, Patna, Banga-
lore, Poona, and Ahmedabad and the hill stations where most of British 
Indian officialdom lived and worked for more than half the year—Simla, 
Darjeeling, and Ootacamund. A lively urban culture developed here; the 
cities and towns of British India were the locations of the successes of the 
colonial economy and polity, of populations of British, Anglo-Indian, and 
educated Indians as well as migrant laborers, traders, and small and large 
manufacturers. Many Indians benefited from the colonial experiments in 
institution building; universities and colleges, medical schools, hospitals, 
municipal government and local politics, and a print culture all originated 
and took root in the colonial cities; these in turn informed the emergent 
public sphere in urban colonial India.
As historians have pointed out, although the making of a modern 
middle class in India was a fragmented and ambivalent process, a middle-
class identity was nonetheless self-fashioned through a pursuit, in many 
forms, of modernity.18 This was a conflictual and often contradictory pro-
cess, involving new and older ideas of social relationships in the emergent 
middle-class worldview, a process that can be discerned from the late nine-
teenth century onward.19 The content of this modernity was also imbued 
with a deep engagement with modern science as well as ancient Indian 
epistemology, including medicine.20 Therefore, embedded as their con-
sumption became in middle-class (however ambivalently self-conscious) 
households, therapeutic products assumed both political and commercial 
overtones; it straddled both the modern and “scientific” as well as the 
supposedly ancient and long-validated epistemologies and commodities. 
The middle classes’ own engagement with modernity was imbued with 
a reconstruction of the idea of antiquity and ancient tradition. While 
the Indian middle class had emerged from the early nineteenth-century 
18. Douglas E. Haynes and Abigail McGowan, “Introduction,” in Towards a History of 
Consumption in South Asia, ed. Douglas E. Haynes, Abigail McGowan, Tirthankar Roy, and 
Haruka Yanagisawa (New Delhi: Oxford University Press, 2010), 1–25.
19. Sanjay Joshi, “Introduction,” in Fractured Modernity: Making of a Middle Class in Colonial 
North India, ed. Sanjay Joshi (New Delhi: Oxford University Press, 2001), 1–22.
20. For the Indian fascination with modern science and technology, see Pratik Chakrab-
arti, Western Science in Modern India: Metropolitan Methods, Colonial Practices (Delhi: Permanent 
Black, 2004); Shiv Visvanathan, A Carnival for Science: Essays on Science Technology and Develop-
ment (Delhi: Oxford University Press, 1997); David Arnold, Everyday Technology: Machines and 
the Making of India’s Modernity (Chicago: University of Chicago Press, 2013).
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colonial establishments, the drug market in turn had developed from 
eighteenth-century encounters between the commerce of the East India 
Company (EIC) and indigenous trade. The drug market and middle-class 
engagement with medicine (political and therapeutic) were mutually 
constitutive. The two had distinctive roots.
In eighteenth-century India, both Western and indigenous medicines 
depended on herbs and their extracts, minerals, and animal matter. The 
EIC surgeons depended greatly on the local markets; their medical items, 
commonly known as “bazaar medicines,” included hundreds of botani-
cal and mineral products locally available from indigenous drug sellers 
who were also spice merchants.21 Throughout the eighteenth and early 
nineteenth centuries, bazaar medicines constituted a significant although 
declining proportion of the EIC’s total expenditures on therapeutics. 
Later, these supplemented the total quantity of drugs used by government 
medical institutions. The trade in therapeutic products was differentiated 
according to both scale and production; at one end were the “European” 
drug houses that catered to the British Indian community and to the aris-
tocratic and the affluent, at the other were the drug sellers in local bazaars 
who sold drugs as well as locally made generic medicines. Within this wide 
spectrum were the importers, traders, and manufacturers of indigenous 
and allopathic remedies and retailers and distributors who participated in 
the vast subcontinental drug market. The difference between indigenous 
drugs and Western ones occurred mostly in the processing stage.
In the nineteenth century, the hospitals and charitable dispensaries 
that were supported by the colonial state predominantly used drugs pro-
cured from England. At this time, Britain imported a huge amount of bulk 
drugs from India; these were then processed and re-exported at much 
higher prices. A large proportion of drugs were bought by the Indian 
army in India for the use of its troops in their hospitals. The army also 
extensively purchased from abroad all kinds of pharmaceutical prepara-
tions and proprietary medicines. Since the expansion of the hospital sys-
tem in colonial India was first undertaken and then overseen by military 
administration, the supply of medicines to them was undertaken by the 
medical department of the government.22 Therefore the government was 
the biggest purchaser of medicines at the turn of the century. The Medi-
cal Store Depots (MSDs), located at Calcutta, Bombay, Madras, Lahore, 
and Rangoon, also purchased drugs and chemicals in the bazaars and 
21. Mark Harrison, Medicine in an Age of Commerce and Empire: Britain and Its Tropical Colo-
nies, 1660–1830 (Oxford: Oxford University Press, 2010), 22.
22. India Office, “Report of the Committee on the Supply of Drugs for India” (1875), 
APAC, IOR/L/MIL/7/15141.
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processed them in their own factories. The government was both manu-
facturer as well as supplier of medicine to the government-aided hospitals 
and dispensaries. Although it processed some local drugs in its factories, 
in the late nineteenth century the MSDs preferred to patronize firms 
from England. Large manufacturing firms in England had their agents in 
Bombay or Calcutta who negotiated contracts with government on their 
behalf.23  Until decolonization (except in the years of the two wars), the 
bulk of the purchases by MSDs were from Britain. This was the cause of 
great resentment on the part of Indian manufacturers and importers.24 
This pressure assumed political proportions when nationalist Indians 
joined the Indian manufacturers in pressuring the MSDs to purchase 
Indian (India-manufactured Western and indigenous drug) products.25
The Heterogeneous Marketplace
The private market flourished outside of government-aided institutions. 
In the early twentieth century, urban areas in British India became the 
sites of competition for the distribution and sale of numerous medicines 
imported from Britain, Germany, the United States, and even Japan. 
This also facilitated the entry and presence of several pharmaceutical 
multinational companies (MNCs), and the Indian market became a 
lucrative area for foreign companies. Some of the companies involved 
in exporting pharmaceutical products to India included Wellcome Bur-
roughs (UK), Burgoyne and Burbidges (UK), Parke, Davis and Company, 
(United States), Merck (Germany), and Bayer (Germany). The consumer 
market in pharmaceutical products refers not only to drugs, but also to 
aerated water, hair oil, creams and ointments, toothpaste, aphrodisiacs, 
and innumerable tonics. The drugs included patented medicines as well 
as generic cholera pills, “fever pills,” “stomach pills,” and aphrodisiacs. 
The identification of diabetes as a widespread condition among middle-
class Hindu men also raised the specter of “performative degeneration” 
23. “Medical Supplies to Local and Municipal Boards,” Indian Med. Rec. (henceforth 
IMR) 6 (1894): 148.
24. For instance, see representations from Smith, Stanistreet and Company and the 
Union Drug Company to the Drugs Enquiry Committee in 1930, “Report of the Drugs 
Enquiry Committee” (Calcutta, 1931), 131.
25. Complaints from Indian manufacturers that the government stores department 
refused to patronize their products, not only medicine but also steel and machine tools, 
were continually propagated by the nationalist Indian Merchants Chamber in the interwar 
years. See chairman’s address, “Annual Report of the Indian Merchants Chamber, 1922–23” 
(Bombay, 1923), 49.
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of the Hindus vis-à-vis the supposedly stronger and more virile Muslims 
(as well as the British), which in turn enlarged the market for “tonics” 
that promoted, expansively, vitality and vigor.26 The development and 
dissemination of nutrition research in the interwar years subsequently 
encouraged the sale of vitamin products.27
In the late nineteenth century, the bulk of the drugs were sold by British 
or European importers. They were based in the colonial metropolises of 
Calcutta, Bombay, and Madras and catered mostly to the European (white) 
clientele both in the cities and in the hill stations, district headquarters, 
industrial enclaves, and commercial hubs where the British population 
of India resided. The largest of the agencies were Treacher and Company 
(Bombay and Poona, Figure 1), Kemp and Company (Bombay), Messrs 
Phillip and Company (Bombay), Frank, Ross and Company (Calcutta), 
Bathgate and Company (Calcutta), Martin and Harris (Calcutta), Stanis-
treet, Smith and Company (Calcutta), Symes and Company (Simla and 
Ambala), and W. E. Smith and Sons (Madras).
26. For an argument that the concept of race in colonial India could be essentialist as well 
as “performative,” i.e., changeable through diet, see David Arnold, “Diabetes in the Tropics: 
Race, Place and Class in India, 1880–1965,” Soc. Hist. Med. 22 (2009): 245–61.
27. See advertisement for Diabetrine by K. C. Mitter’s firm, IMR 32 (1912): ix; “Notes 
on New Preparations,” Med. Digest 2 (1934): 58; advertisement for Berin by Glaxo Lab. Ltd., 
Calcutta Med. J. 42 (1945): ix.
Figure 1. The Treacher and Company Building, Bombay, 1894. Wellcome Library, 
London.
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These firms sold at retail; but this was only part of their widespread 
business concerns. They also procured and sold wholesale drugs for 
large British-owned companies in India, including several rail and tea 
companies and collieries that dispensed basic drugs such as compounds 
of cinchona on a large scale to their workers, or to the native states that 
built therapeutic institutions for the public, such as in Baroda, Travancore, 
and Hyderabad.28 Pharmaceutical companies in Britain and Germany also 
appointed their own agents who negotiated contracts on their behalf with 
the large wholesale firms, with one agent sometimes working for two or 
even three firms simultaneously.29 So there was a complex hierarchy of 
manufacturers’ agents, wholesalers, retailers, and “bazaar pharmacists” 
who competed with each other; yet it was also a segmented market; the 
prosperous British residents and aristocratic Indians patronized the large, 
European-styled retailer–manufacturers while others resorted to bazaar 
traders or itinerant drug sellers of all descriptions.
British residents in India patronized “European” (British-owned) 
establishments to supply them with many necessities. Imports included 
umbrellas, cutlery, photographic equipment, perfumes, cosmetics, sewing 
machines and gramophones, preserved fruits, medicated wines, brandies 
and spirits, tobacco, canned meats, cocoa, chocolate, and, invariably, bot-
tles of patent medicines, powders, and medicine chests.30 The expansion 
of the bureaucracy and military establishments of the Raj in the post-1858 
period fostered a larger community of British consumers of European 
medical and allied goods. Prospective civil servants, visitors, and mission-
aries who might live away from urban centers were advised to purchase 
a “medicine chest” from a manufacturer in Britain before embarking on 
the journey.31 By 1887, distributors in Bombay and Calcutta were sending 
their representatives to the hill stations and cantonment towns in northern 
28. The prosperous, princely state of Baroda, for instance, regularly used both the 
pharmaceutical manufacturing and trading firms of Treacher and Co. and Kemp and Co. 
of Bombay to order the delivery of medicines, chemicals, telescopes, opera glasses, cigars, 
and wines and spirits. Baroda Record Office, Huzoor English, 99/127/19, 1875–79.
29. For instance, “Pharmacy in India,” Chemist & Druggist (henceforth C&D),, October 2, 
1886, 448; “Bombay Medical Congress from the Pharmaceutical Point of View,” Pharmaceuti-
cal Journal and Pharmacist, March 20, 1909, 409; “Personal Paragraphs,” Indian and Eastern 
Druggist (henceforth IED), July 1920, 25.
30. For a fascinating study of the use and cultural appropriation of Western machine-
made products such as sewing machines and typewriters (gramophones, cameras, and clocks 
would fall into this category), see Arnold, Everyday Technology (n. 20), esp. 40–68.
31. Francis Hogg, Practical Remarks Chiefly Concerning the Health and Ailments of European 
Families in India, with Special Reference to Maternal Management and Domestic Economy (Benares: 
Medical Hall Press, 1877), iii.
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and southern India, opening new branches as well as contacting medical 
practitioners directly. The British trade journal Chemist & Druggist urged 
ambitious pharmacists in Britain to look for opportunities in India.32 
These pharmacies provided for Europeans as well as aristocratic Indians; 
most of their products were too expensive for Indian pockets, even those 
of the middle and professional classes.
Although BP was the standard-bearer for drug sales in India, there was 
no legislation to enforce its preeminent position. In the absence of either 
a food and drugs law or a self-governing body of pharmacists, the quality 
of the goods varied; therefore, each prominent retail store depended on 
its own name brand for marketing. In many cantonment towns and hill 
stations, these stores were part of the commercial landscape. The Bom-
bay-based Treacher and Company had achieved a virtual monopoly over 
European pharmaceutical products in Poona, a cantonment town near 
Bombay. A guidebook for visitors to Poona pointed out that the street 
where their outlet was located was known informally as Treacher Road.33 
The manufacturer–importers Bathgate and Company and Stanistreet, 
Smith  and Company (Figure 2) both featured as predominant aspects of 
the cityscape of Calcutta in a popular Bengali satire on British rule and 
its impact on India.34
The British Indian traders in Bombay, Madras, Rangoon, and Cal-
cutta engaged directly with suppliers from Britain as well as their agents. 
One prominent agent, Mr. Charles W. White, for instance, represented 
Burgoyne, Burbidges and Company, A. F. Pears, as well as Wellcome Bur-
roughs and Company in India. While he was a larger-than-life figure, well 
known to all British and several Indian wholesalers, he was only one of 
several.35 These distributor–manufacturers used English dailies and peri-
odicals as well as printed catalogues and circulars posted by mail order to 
reach their consumers. They marketed through advertisements in newspa-
pers and periodicals in English, evangelical periodicals, regional-language 
newspapers, and medical journals.36 In the early twentieth century, there 
was a boom in medical publishing in India on the back of the medical 
manufacturers, retailers, and agents who advertised heavily there. The 
32. “Indian Pharmaceutical News,” C&D 29 (1886): 235; and “Pharmacy in India,” C&D 
29 (1886): 448.
33. Guide to Poona and Kirkee, with Directory, for the Season 1876, etc. (Bombay: Treacher 
and Co, 1876).
34. Durgadas Rai, Debgoner Mortye Agaman (Calcutta: Gurudas Chattopadyay and Sons, 
1929), 498–502, 548.
35.  “Pharmacy in India,” C&D 30 (1889): 239.
36. For instance, see Bombay Guardian, January 5, 1901, 1.
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distributors also directly canvassed medical professionals, both official 
and unofficial.
The need for advertising and canvassing seems evident because of com-
petition from Indian distributors and importers. Nonetheless, distributors 
of “British-made” imported pharmaceutical products enjoyed unrivalled 
status and an almost mystical reputation for “quality,” as did any other 
consumer product that was imported, especially from the metropolis.37 
The privilege of displaying well-known British names was treasured by dis-
tributors in India. British companies provided their own labels with space 
for the distributors to place their own agencies’ names and addresses, 
highlighting both the manufacturer and the wholesaler. In spite of their 
reputation, the BP standard was not necessarily maintained by all British 
distributors because the market remained unregulated.38 At the turn of 
the century, India (along with Southern Africa and Australia) was one 
Figure 2. The hall of Stanistreet, Smith and Company’s pharmacy, Calcutta, 1902. 
Wellcome Library, London.
37. Chris Furedy, British Tradesmen and Shopkeepers of Calcutta, 1830–1900 (York: published 
by author, 1976), 9. Also see Herbert Compton, Indian Life in Town and Country (London: 
G. Newnes, 1904), 145.
38. “Report of the Drugs Enquiry Committee” (n. 24), 86.
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of the developing markets for the drug trade in the global expansion of 
the industry, and it is not surprising, therefore, that trading within India 
was an emerging focus of drug exporters from Britain, America, and the 
Continent. There are no reliable records for the total amount of manu-
facture and trading in drugs and pharmaceuticals in British India at this 
time. But apart from various anecdotal sources, a perusal of the number 
of companies that paid custom duties for the import of “spirituous mate-
rial,” largely for use in tinctures and drugs, provides us with the names 
of dozens of exporters from England, France, Germany, and America.39
In addition to the luxurious displays in the Europeanized commercial 
streets of British India, there also lurked a large bazaar market, catered to 
by Indian distributors and wholesalers. The term “bazaar” typically denotes 
an Oriental marketplace, an essentialized, chaotic, and exotic space. His-
torians of the marketplace in India have pointed out that the bazaar was 
far from a quintessentially exotic marketplace and therefore subordinate 
to the European capitalist market.40 As Pratik Chakrabarti has argued, 
in the eighteenth century the bazaar represented the constructed space 
where European merchants met with Indian interlocutors to buy local 
therapeutic products, often in unprocessed form, that were then traded 
overseas.41 It was also where European surgeons found “bazaar medicine” 
for use in their own armies and hospitals. Late Victorian pharmacists in 
Britain referred to all Indian traders and merchants as “bazaar traders”; 
it was a racialized term, imbued with the threat that Indian traders and 
wholesalers posed to the prominent British Indian firms. Indian import-
ers and wholesalers often preferred to patronize German, Japanese, and 
American manufacturers and undercut the prices of the more prominent 
and visible British manufacturers and their agents and distributors in 
India. Indeed, as an editorial in the British trade journal Chemist & Drug-
gist pointed out at the turn of the century,
The drug-trade is changing . . . the strictly English pharmacies do not multiply, 
as they are needed solely by the white people and richer natives. The bulk of 
the people get their medicines from the bazaar druggists, who are becoming 
39. Alphabetical List of Drugs, Medicines and Other Preparations Free from, and Containing, 
Spirit, Compiled from the Results of Tests Made by the Customs Houses at Calcutta, Bombay, and 
Madras (Madras: Superintendent of Government Press, 1903), 1.
40. Rajat Kanta Ray, “Asian Capital in the Age of European Domination: The Rise of the 
Bazaar, 1800–1914,” Mod. Asian Stud. 29, no. 3 (July 1995): 449–554.
41. Pratik Chakrabarti, “Medical Marketplaces beyond the West: Bazaar Medicine, Trade 
and the English Establishment in Eighteenth Century India,” in Medicine and the Market in 
England and Its Colonies, c.1450–c.1850, ed. Patrick Wallis and Mark Jenner (Basingstoke: 
Palgrave Macmillan, 2007), 196–215.
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more numerous. They are keen buyers, because they are the keenest sellers 
in the world. . . . German firms are now keen competitors, . . . and do direct 
business with the bazaars.42
The bazaar market, in fact, had thrived in the late nineteenth century and 
encompassed not only botanical and mineral products, but also a great 
number of processed therapeutic products that included “tinctures, pills, 
and homeopathic medicines . . . and locally-made instruments.”43 There 
was a continuum, therefore, between the large global drug sellers and the 
so-called bazaar traders who were also a segmented lot.
The bazaar traders catered to the large numbers of middle- and lower-
class urban Indians. They encompassed the occupational descendant 
of the spice merchant who provided bazaar medicine to the large-scale 
importers and distributors of European pharmaceutical products. Despite 
competition and racialized interactions, the bazaar traders negotiated and 
partnered with the more prestigious British Indian importers. The agent 
and proprietors of B. W. and Company, for instance, were enraged when 
they discovered that British importers in Madras, W. E. Smith and Sons, 
were passing on a part of their “unique” discount for certain branded 
products to the Indian distributors, H. S. Abdul Gunny and Company, 
of Calcutta. Their agent sent stern warnings to cease the practice; but 
in a diverse market, even the British Indian distributors moved beyond 
their European niches to participate in the bazaar trade in pharmaceuti-
cal goods.44
The Indian distributors proved more flexible than the large British 
pharmacies and resorted to importing from Germany, the United States, 
and Japan at cheaper rates for similar products. As a visiting American 
pharmacist commented in the late nineteenth century, “The patent medi-
cine trade is large, but it is much hampered by the natives, who sell at 
prices that Europeans cannot touch.”45 In 1892, the Indian Medical Record 
estimated that in Calcutta alone there were around 756 druggists busi-
nesses and divided them into three grades: from the electrified, beau-
tifully presented showrooms to the crowded wholesalers in the native 
bazaar.46 Similarly, Bombay had a large number of Indian druggists-cum-
manufacturers. The British Indian pharmacists generally alleged that 
42. “Current News on Export Trade: India and Ceylon,” C&D 66 (1905): 375.
43. “A Report of the Exhibits of Drugs, Chemicals, Instruments, etc. in the Calcutta 
International Exhibition,” C&D 26 (1884): 115.
44. B. W. and Co. to W. E. Smith, March 28, 1906 (henceforth WA[Wellcome Archives]), 
WF/E/03/21, box 114.
45. John A. Falck, “Pharmacy in India,” C&D 30 (1887): 441–42.
46. “The Chemist and Druggist Trade in Calcutta,” IMR 3 (September 1, 1892): 350.
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bazaar pharmacists bought adulterated and inferior medical products, 
“cheap bazaar catch-lines from Great Britain.”47 Indian traders in fact 
often favored German products because of the attention they afforded 
to the market. As an Indian trader pointed out, the British trader needed 
to “adapt himself more to the requirements, tastes and prejudices of 
the millions in India,” just like the German exporters.48 These included 
looking at cultural demands in the market, from narrowing the size of 
marrow spoons to suit the size of Indian sheep to selling whole canned 
fruit because of the Hindu taboo regarding eating fruit cut by people of 
a different caste.
The flourishing market lent impetus to the increasingly large propor-
tion of the non-British share of the Indian medical market in the twentieth 
century. Indian drug sellers began to manufacture their own products, 
including patent and proprietary medicines, especially the ubiquitous 
fever, cholera, and dysentery pills. The devastating plague epidemic of 
1894–96 in Bombay resulted in drastic government public health measures 
and led to several indigenous “cures” that were both sold in the open 
market as well as peddled to government hospitals.49
One of the largest firms in India, B.  K. Paul of Calcutta, was both 
importer and producer of medicines; it began as a small family firm and 
by 1905 employed around three hundred assistants in retail outlets in 
Calcutta alone (Figure 3). For a time before World War I B. K. Paul even 
enjoyed “the distinguished and (to a Bengali) rare honor of Viceregal 
patronage” of the governor of Bengal.50 The firm manufactured its own 
patent medicines, homeopathic medicines, surgical instruments and 
imported and distributed pharmaceutical products from Europe and 
North America.
B. K. Paul’s main retail establishment in Calcutta rivaled in display 
any other British Indian pharmacy. After the expansion of the company 
during World War I, it employed over fifteen hundred workers.51 Imme-
diately after the war, the grandson of the founder, H. N. Paul, led the first 
short-lived professional body of pharmacists, the Calcutta Chemists and 
Druggists Association, which lobbied for favorable exchange rates from 
British banks in Calcutta.52 B. K. Paul featured in medical trade directories 
47. “Indian Incursions,” British and Colonial Druggist, March 31, 1911, 257. Such com-
plaints spanned some fifty years, until the Drugs Enquiry Committee of 1930. For instance, 
“Pharmacy in India,” C&D 33 (1888): 552; “Indian Drugs Inquiry,” C&D (1931): 249.
48.  “India and the German Traders,” Indian Trade Journal, April 16, 1908, 100–101.
49. Mukharji, Nationalizing the Body (n. 12), 179–212.
50. “The History of a Pharmacy,” IMR 29 (1909): 185.
51. C&D 104 (1926): 757–60.
52. C&D 93 (1921): 70.
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published in Britain, along with Wellcome Burroughs, Boots Pure Drugs 
Company, Parke, Davis and Company, and the British Indian companies 
of Calcutta and Bombay.53
B. K. Paul’s success story, unique for a Bengali-owned company, has 
been interpreted by Mukharji as a talismanic story of Bengali entrepre-
neurial success that was acceptable to contemporary middle-class Benga-
lis as a nationalist and entirely philanthropic success. In the process, the 
firm and its owner, Butto Kristo, have been understood as representing 
a crystallization of a new kind of drugs trader, marginalizing the older, 
subaltern herb collectors and gatherers who have remained nameless in 
Bengali nationalist iconography. Mukharji’s claims are tenuous on two 
grounds. First, the loyalty of the Bengali middle class toward indigenous 
drugs was ambivalent. They were often biased in favor of foreign-produced 
drugs.54 Nationalist loyalty toward pharmaceuticals was divided, where 
Figure 3. Front of Butto Kristo Paul’s stall, Calcutta, 1902. Wellcome Library, 
London.
53. E. J. O’Meara, Medical Guide for India and Book of Prescriptions (London: Butterworth, 
1920), 647–48.
54. Even in 1940, one Bengali physician pointed out that “some Indian doctors will not 
prescribe any medicine, which is not of British origin.” S. B. Banerjea, “Drugs in India,” 
Indian and Eastern Chemist, February 1940, 39.
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European manufactured products were highly regarded. Second, B. K. 
Paul continued an older tradition of family firms that dealt in wholesale 
markets—except that the challenges were new. The dominating presence 
of Anglo-Indian manufacturers and distributors lent a racial edge to the 
competition. Butto Kristo was not an educated pharmacist in the Western 
medical tradition. His success was derived from the family’s nineteenth-
century presence in the bazaars.55
Other large Indian bazaar traders flourished as well, especially in 
Bombay, where indigenous capital had a freer rein than it did in east-
ern India.56 N. Powell and Company was established around 1889 by an 
Indian, A. L. Nair. His company traded in imported pharmaceuticals and 
surgical instruments and manufactured surgical instruments. In 1909, he 
was the only non-European importer and distributer who exhibited his 
products at the exhibition of the Bombay Medical Union; by this time his 
company was the Indian agent of several exporters too.57 N. Powell and 
Company led an informal association of Bombay chemists and druggists, 
especially lobbying on behalf of the Indian merchants.58 After World War 
I, the proprietor toured Britain and the Continent in order to canvass for 
agencies from foreign exporters.59 In the 1930s, the company was com-
mended as the producers of the best-quality surgical instruments, asthma 
tablets, cod liver oil, chlorodyne, cough medicine, kidney pills, liver pills, 
lung tonic, health salt, quinine tablets, and tonics, all of which could, the 
nationalist Bombay Medical Union declared, replace foreign imports.60 
Rather than bearers of cultural identities, both B. K. Paul and N. Powell 
need to be seen as components of a new structure of drug markets in the 
early twentieth century.
Meanwhile, rising nationalist aspirations from the late nineteenth 
century highlighted the economic exploitation of the colonial state. 
55. Butto Kristo was from the “spice merchant” subcaste and one of the many absentee 
landlords from trading families who owned estates in rural Bengal and lived in Calcutta. 
Meera Guha, “Growth of Calcutta’s Business District,” Econ. Polit. Weekly 17, no. 46 (Novem-
ber 13, 1965): 1695–98.
56. A. K. Bagchi, Private Investment in India, 1900–1939 (London: Routledge, 2000), 
157–216. This changed after World War I. Ibid., 192–95; B. R. Tomlinson, “Colonial Firms 
and the Decline of Colonialism in Eastern India 1914–47,” Mod. Asian Stud. 15, no. 3 (1981): 
455–86; C. Markovits, Indian Business and Nationalist Politics 1931–31: The Indigenous Capitalist 
Class and the Rise of the Congress Party (Cambridge: Cambridge University Press, 1985), 10.
57.  “Bombay Medical Congress: From the Pharmaceutical Point of View,” Pharmaceutical 
Journal and Pharmacist, March 20, 1909, 409.
58. C&D 96 (1922): 45.
59. IED 2 (1921): 194.
60. All India Swadeshi Directory (Ahmedabad: Gujarat Sahitya Mandir, 1931), 385–88.
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Nationalists decried the decline of India’s manufacture as the cost of 
industrialization in England and advocated economic nationalism. With 
large-scale protests at the partition of Bengal in 1905, the swadeshi move-
ment led a boycott of foreign goods and supported indigenous manufac-
turing.61 Throughout the nationalist struggle, swadeshi remained a great 
force in Indian politics. Between 1905 and 1907, several Indian chemical 
and pharmaceutical companies emerged; these were distinct from the 
druggists-cum-manufacturers. They were established by chemists who 
were trained in scientific techniques and interested in setting up labora-
tories that would manufacture pharmaceuticals to compete directly with 
imported pharmaceuticals. Two prominent scientists—P. C. Ray, a profes-
sor of chemistry who started Bengal Chemicals and Pharmaceutical Works 
(BCPW) in Calcutta, and T. K. Gajjar, also a chemistry teacher—partnered 
with B. D. Amin, a trader, and established the Alembic Chemical Works 
(Alembic) in Bombay in 1902. In 1907, Alembic moved its factory to 
Baroda, a princely state in western India. The generous patronage of the 
modernist ruler of Baroda, Maharaja Sir Sayajirao III, enabled them to set 
up a large factory, and their specialty was the production of alcoholic tinc-
tures, fruit essences, and perfumery.62 BCPW, celebrated in independent 
India for its pioneering pharmaceutical production, competed directly 
with the MNCs as well as European distributor–pharmacists. In fact, emer-
gent Indian pharmaceutical companies competed for the same market 
and manufactured both Western and Ayurvedic medicines. Some of them 
did not retail their products but instead concentrated on distribution of 
their goods wholesale to all of India. They also took the opportunity to 
display their products at industrial exhibitions in India, especially once 
the swadeshi movement for economic nationalism gained in momen-
tum. As Lisa Trivedi has argued, the exhibitions served to delineate the 
geography (and the culture) of the aspiring nation.63 These exhibitions 
defined the nation as much as the imperial exhibitions of the Victorian 
era had defined the reach and power of the British Empire. The Indian 
National Congress organized the first Indian Industrial and Agricultural 
Exhibition in 1901 in Calcutta, and in succeeding years to Ahmedabad, 
Bombay, Madras, and Benares, all intensely urban manufacturing or trad-
ing centers. By the time it came around again to Calcutta in 1906–7, it 
61. For a fuller account of the swadeshi movement in its earlier phase, see Sumit Sarkar, 
The Swadeshi Movement in Bengal, 1903–1908 (Ranikhet: Permanent Black, 2011).
62. B. D. Amin, The Rise and Growth of the Alembic Chemical Works: A History (Baroda: 
Alembic Printing Press, 1939), 2–5.
63. Lisa N. Trivedi, “Visually Mapping the ‘Nation’: Swadeshi Politics in Nationalist India, 
1920–1930,” J. Asian Stud. 62, no. 1 (February 2003): 11–41.
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attracted manufacturers from all over India and included about a thou-
sand exhibitors.64 The manufacturers in the soaps, chemicals, and perfum-
ery and confectionary sections all provided Indian alternatives to imported 
products, with the added attraction of reduced prices for middle-class 
consumers.65 The new pharmaceutical companies like BCPW and Alembic 
as well as the older importer–manufacturers like B. K. Paul won awards 
for the best quality products in therapeutic goods.66 Whereas the firms 
established by modern chemist–nationalists like P.C. Ray and T. K. Gajjar 
were not classed as producing “bazaar medicine,” those of B. K. Paul and 
N. Powell, who were distributors as well as manufacturers, definitely fell 
into that category. The nationalist activism of Ray and Gajjar has served to 
highlight their importance in Indian industrialism in nationalist discourse. 
Historians have also argued that they both were pioneers (particularly Ray, 
a nationalist) of the pharmaceutical industry in British India.67 They have 
neglected to indicate that their entrepreneurship was part of a broader 
trajectory that included manufacturers becoming drug importers and 
dealers. There was a continuum, therefore, from the so-called bazaar 
dealers to the scientifically trained manufacturers that involved import-
ers, distributers, and producers. The critical element of this market was 
not the heterogeneity of its sellers, although that was relevant, but that a 
single drug could be imported or processed, distributed, and consumed 
in many different forms, potencies, and prices, very seldom in conformity 
with BP. The most obvious example of this is the trade in quinine and its 
alkaloids—these were sold in several potencies and differing prices across 
the country.68 There was an inherent lack of standardization.
64. A Report of the Indian Industrial and Agricultural Exhibition, Calcutta, 1906–7 (Calcutta: 
Industrial India Office, 1907), v.
65. Ibid., xxii.
66. Ibid., 106–13.
67. See, for instance, Pratik Chakrabarti, “Science and Swadeshi: The Establishment and 
Growth of the Bengal Chemical and Pharmaceutical Works 1893–1947,” in Science and Mod-
ern India: An Institutional History, c.1784–1947, ed. Uma Das Gupta (Delhi: Pearson, 2010), 
117–42; D. Tripathi and M. Mehta, Business Houses in Western India: A Study in Entrpreneurial 
Response, 1850–1956 (London: Jaya Books, 1990), 116–30.
68. From the five-grain “pice” packets distributed through post offices to the more 
potent and expensive varieties available in the famous retail units. Proceedings of the Lieu-
tenant Governor of Bengal, Municipal Department, Medical Branch, Calcutta June 1911, 
P/8687/APAC, 6–8; “Profits on the Manufacture of Quinine,” Lancet, September 9, 1905, 
801–2. See Patricia Barton, “Powders, Potions and Tablets: Politics, Science and the Purity 
of Drugs in British India, 1890 to 1939,” in Drugs and Empires: Essays in Modern Imperialism 
and Intoxication 1500–1930, ed. James Mills and Patricia Barton (Basingstoke: Palgrave 
Macmillan, 2007), 142–61.
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Adulteration in a Heterogeneous Market
One reason for widespread adulteration was that government regulation 
was light. There was no food and drugs law in colonial India; laws regu-
lating the sale of poisons and narcotics like cocaine evolved piecemeal. 
In Bengal all pharmacists selling British pharmaceuticals containing any 
form of poison had to be registered, but this law hardly precluded hun-
dreds of sellers from trading in the informal market. In Bombay, a similar 
act could be enforced only on the pharmacies in the metropolis, and then 
only the larger ones.69 For medico-juridical purposes, the government 
appointed three chemical examiners, at Bombay, Calcutta, and Madras, 
whose duty, among many, was to examine foods and other substances sold 
in the market and those seized by authorities, usually in cases of grave ill-
ness or the death of a consumer. The government’s all-India Poison Act 
was passed in 1904 after a decade of deliberation; its implementation was 
fragmentary at best.70
Among the elite medical officials of the Indian Medical Service, there 
were discussions on limited regulation of the drug market. These con-
tinued until the interwar years, when public pressure fueled by Indian 
newspapers and lobbying by the most prominent British and Indian 
manufacturers succeeded in the appointment of a drug standardization 
committee by the government in 1930. Effectively, there was no control 
over the drug market in late colonial India.
In official discourse, the preexistence of a large, informal market in 
variable drugs were supposed to have prevented any legislation to con-
trol it. In 1894, at the very first the Indian Medical Congress at Calcutta, 
two IMS officials, one a Bengali physician, read a paper together on the 
sale and “ease of distribution” of poisons in India. They pointed out that 
the chemical examiners at Calcutta and Madras particularly had found 
hundreds of deaths by poisoning and urged the need for legal control. 
But the elite IMS officials claimed that it was “Utopian” for India to have 
a poison schedule similar to Britain’s.71 Even after the Indian Poisons 
Act was enacted, the Bombay Gazette highlighted that only druggists sell-
ing BP products were covered in terms of the law, whereas Indian medi-
cines were exempt, and moreover, “Bunneahs and small dealers sell any 
number of drugs.”72 Whereas the Poisons Act referred only to poisons 
69. A. C. Allen, “Note on the Indian Poisons Act,” Pharmaceutical Journal and Pharma-
cist, August 28, 1909, 309; “The Indian Poisons Act,” Pharmaceutical Journal and Pharmacist, 
October 16, 1909, 470.
70. Allen, “Note on the Indian Poisons Act” (n. 69).
71. Bombay Gazette, January 4, 1895, 4.
72. Ibid.
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and narcotics, the quality of drugs or other products was not regulated. 
These varied enormously and were a rich source of contention between 
competing European importers as well as among Indian dealers. The 
bulk of the blame for the preponderance of substandard products fell 
on the bazaar traders, from the large wholesale importer to the modest 
pavement drug seller.
The adulterated market was vast; it included imitations of well-known 
imported branded products like soaps, powders, and patent medicines 
as well as bulk products like olive and almond oils. In 1889, Charles W. 
White, the British agent for B. W. and Company, A. F. Pears and Company, 
and Burgoyne, Burbidges and Company of England, claimed on one 
visit to India that German, French, and American competition, with the 
full complicity of the Indian wholesalers, was marginalizing the British 
manufacturers with brazen adulterated oils and powders: “calomel con-
taining 50% of chalk, santonin half boracic acid, sent here from France 
and Germany carriage paid and sold in the currency of the country, I fail 
to see how honest British competition can stand.”73 White successfully 
challenged the sale by dealers in Bombay of the popular Pears glycerin 
soap, allegedly supplied from Germany.74 In the next year, Bertie Smith, a 
British wholesale importer of drugs based in Bombay, identified “German 
competition” as his problem, and accused Continental firms of monopo-
lizing trade in certain drugs by exporting cheap, adulterated material to 
“native” drug importers.75 An anonymous Indian correspondent of the 
British trade journal Chemist & Druggist claimed that an “American-made 
bazaar counterfeit” of an English brand of patent drug made from sarsa-
parilla flourished in the Indian market.76
In 1905, an impassioned appeal by the Parsi physician Dosabhai Ras-
tamji Bardi, who taught at the Grant Medical College in Bombay, demon-
strated the extent of the adulteration in food and drugs. Citing records 
of the Chemical Examiners of Bombay from 1872 to 1902, Bardi claimed 
that there was consistent adulteration of imports to the Indian market:
It is necessary to remember that the retail druggist hardly adulterates them, 
but as people want cheap drugs, he buys adulterated articles . . . no wonder 
that medical men are disappointed in their treatment. Bombay, and for the 
matter . . . the whole of India, depends on European and American markets 
for their supply of drugs, at any rate of all important pharmaceutical and 
chemical preparations.77
73. C&D 34 (1889): 239.
74. Ibid.
75.  “A Talk on the Indian Drug Trade,” C&D 37 (1890): 71.
76. “Proprietaries in India,” C&D 55 (1899): 1077.
77. Bombay Medical and Physical Society Proceedings 9 (1905): 5–61.
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Colonial historians have not engaged with the problem of adulteration 
in the Indian drug market. Contemporary analysis of the Indian drug 
market was one of adulteration and the lack of drug control; in both offi-
cial and medical discourse, adulteration was linked largely to the bazaar 
market, Indian manufacturers of both Western and Indian medicine, and 
unscrupulous importers who dealt with products from the Continent. The 
official and medical rhetoric suggested that the respectable end of the 
market was dominated by British Indian manufacturers and importers. 
The professionalization of pharmacy is also the predominant theme of 
analyzing the history of the drug industry in developed Western nations.78 
Although adulteration or the presence of spurious or diluted medicines 
was an important reality of the Indian market, the lack of professional 
education and self-regulation and corporatization among pharmacists 
provides only a partial analysis of adulteration. What is omitted from the 
analysis of adulteration by contemporary commentators (and indeed the 
rare historian such as Barton has addressed it with reference to quinine) 
is the need for drugs of varying prices to suit the different sections of con-
sumers within the Indian market. This led to drugs of different strengths 
and potencies, often in disguised form, because these differing potencies 
were not recognized by BP.
The case was even more complicated by the widespread use of indig-
enous drugs, which could not be standardized according to BP because 
Western medical professionals suggested that their active principles 
should first be analyzed, a gigantic and impossible task. Adulteration 
therefore covered a spectrum of deficiencies among the drugs sold in 
the market; some were willfully and totally fake medicines, others were 
simply drugs of a lower potency and price.
Examples of adulteration in imports found by the chemical examiner 
of Bombay included the presence of hydrochlorate of cinchonin, a much 
cheaper product, in a sample of quinine sulphate, potassium nitrate con-
taining hydrochloric acid, worm tablets with no santonin, and a sample of 
tartar emetic not conforming to BP tests.79 Importers provided substan-
dard products not only to retail druggists, but also to the government’s 
MSDs. Adulteration and substandard goods was pervasive; the diversity 
and quantity of the therapeutic products on sale in India appeared to defy 
78. D. J. Malleck, “Professionalism and the Boundaries of Control: Pharmacists, Physi-
cians and Dangerous Substances in Canada, 1840–1908,” Med. Hist. 48, no. 2 (2004): 175–98; 
Deborah Anne Savage, “The Professions in Theory and History: The Case of Pharmacy,” 
Bus. Econ. Hist. 23, no. 2 (1994): 129–60; Frederick Kurzer, “George S V Wills and the West-
minster College of Chemistry and Pharmacy: A Chapter in Pharmaceutical Education in 
Great Britain,” Med. Hist. 51 (2007): 477–506.
79. Bombay Medical and Physical Society Proceedings 9 (1905): 27.
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any serious attempt at regulation. BP was the yardstick of quality, and a 
“colonial addendum” to it in 1898 legitimized the “substitution” of several 
drugs for those that were easily available and commonly used in India by 
Western practitioners.80 This addendum was the consequence of a long 
campaign in India by several eminent medical personnel, both British 
and Indian.81 British pharmacists alleged here that the addendum was of 
only academic value: “In India there is no Pharmacy Act; a Pharmacopeia is 
looked upon more as a guide.”82
The fifty-four drugs added to BP in acknowledgment of indigenous 
drugs that could be prescribed by Western practitioners in India made 
little difference to the production or sale of indigenous drugs instead of 
imported ones; and indeed, the major thrust of import substitution and 
production of indigenous drugs began only when World War I severely 
circumscribed the import trade in the Indian drug market.
In this market, therefore, manufacturers and distributers relied heav-
ily on branding and advertising. All major drug companies, both British- 
and Indian-owned, warned against imitations and substitutions cleverly 
produced to fool customers into buying substandard goods. What then 
defined purity to the customer? The pricing provided a guidance of sorts: 
expensive products were considered more efficacious. Even this standard 
was subverted on a regular basis with the production of imitation drugs 
sold in reused packaging from reputable manufacturers, who responded 
by printing warnings against imitation products in advertisements and 
circulars.83 The Indian public, meanwhile, believed that the British firms 
sold their outdated stock at cut-rate prices to bazaar merchants.84
Drug traders provided cheap products to consumers everywhere, 
and there was a wide spectrum between “pure” and “impure” drugs that 
embraced several degrees of authenticity. The only drug that the govern-
ment attempted to distribute widely in India was quinine and its alka-
loids, at first distributed free, and then sold at a nominal price. Through 
inexpensive packets sold at post offices and later through a wide-ranging 
network of distributors, provincial governments sought to limit the devas-
80. GOI Medical, “GMC” (n. 9), 373–78.
81. See the appeal of Kanny Lal Dey in the first Indian Medical Congress in 1895, Phar-
maceutical Journal and Transactions 25 (1894–95): 446.
82. C&D 62 (1903): 117.
83. For instance, in 1912 B. W. and Co. published pamphlets in Tamil, Bengali, and 
Gujarati advertising “tabloid” brand medicines, urging, “Beware of imitation. Take particu-
lar care to buy ‘Tabloid’ medicines which are prepared by BW and Co only.” Circular Book 
18, 1912–13, WA, WF/M/GB/01/19/01, 20–23.
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tation caused by malaria. As Patricia Barton has demonstrated, the high 
levels of adulteration (up to 80 percent) of the quinine tablets sold by 
government agents and other distributors subverted the policy.85
Meanwhile, Indian druggists faced most of the blame for adulteration 
and substandard products in the market. These might include imported 
patent medicines as well as drugs commonly used in both indigenous and 
Western systems of medicine, including belladonna, aconite, senna, and 
asafetida. In 1910, the British and Colonial Druggist suggested that while 
“the native vendor is keen after a bargain, . . . when it is said that he can 
purchase Easton’s syrup in four oz. bottles, each packed in a carton at 36s. 
gross, it appears that the limit of cheapness has been reached.”86
The hugely popular Moore’s medical manual, a handbook of medi-
cine and diet for British residents in India that went through several edi-
tions, cautioned in 1916 that “the adulteration and sophistication of the 
specimens found in the Indian market, and the ariability . . . of the drugs 
themselves . . . renders it quite impossible to use them with safety.”87 From 
the standpoint of both the “legitimate” trades and official medicine, there-
fore, the problem was twofold: dilution and imitation of standard drugs 
and the uncontrollable and uncertain quality of the fresh drugs on the 
market that problematized the indigenous drug market.
Before World War I, public discourse in India recognized that some 
kind of legislation was needed, and in the Upper Provinces one Indian 
councilor referred a request for legislation to the Select Committee in 
1911.88 That same year the Statesman, a Calcutta daily, began a campaign 
against spurious drugs, many of which included diluted or impure drugs 
from Britain, the United States, Germany, and Japan. The debate began 
with a letter from Norman Hirst, a pharmacist who alleged that “they 
send out to India cheap varieties of quinine sulphates; compound extracts 
of sarsaparilla in some instances consisting chiefly of glucose and many 
other medicinal preparations . . . are almost entirely deficient in active 
principle and are practically inert.”89 Hirst demonstrated the complicity of 
both the consumers and the exporters and alleged that the British Indian 
companies needed drugs on a large scale for their laboring populations, 
such as “tea gardens, railway companies, collieries, . . . send round ‘ten-
der forms’ or quotations for their medicines, and they usually accept the 
85. Barton, “Powders, Potions and Tablets” (n. 68).
86. British and Colonial Druggist, August 26, 1910, 183.
87. C. A. Sprawson, Moore’s Manual of Family Medicine and Hygiene for India (London: J. A. 
Churchill, 1916), 1.
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lowest tender.”90 Therefore adulteration in the Indian market needs to be 
understood as a consequence of not simply the traders’ rapacity or lack 
of government control, but also the differential needs and priorities of 
the consumers of therapeutic products.
In the age of nationalism, Indian medical professionals often tended 
to view adulteration at two levels: the failure of self-regulation by the mer-
chants and industrialists and the lack of a professionalization by pharma-
cists. The Indian Medical Record argued for cooperative associations and 
suggested the establishment of an apprentice system to train prospective 
pharmacists.91 Both were distant dreams. The popular movement for a 
drug control policy continued in the Indian press, both national and 
regional. In the interwar years it proved a nationalist issue. The Indian 
press, in a time of intense competition between Indian and British capi-
tal in manufacturing and trade, inverted the charge of adulteration and 
pointed out that British manufacturers and British importers in India 
colluded to release substandard pharmaceutical products in the Indian 
market. In 1925, an article in the daily the Bengalee, reproduced by the 
Indian Medical Record, alleged that all reputed pharmaceutical companies 
in Calcutta, both British-owned and Indian, made a regular practice of 
misleading customers by labeling their products as being of BP strength, 
including BCPW, Stanistreet, Smith and Company, D. Waldie and Com-
pany, and B. K. Paul (distributors of imported products as well as manu-
facturers). It claimed that the chemical examiner of Calcutta had reported 
that “local firms in competition with one another and with the importing 
firms try to reduce the manufacturing cost by using less medicament and 
alcohol, and that the importing firms in their turn have begun a similar 
practice.”92 After a strong protest from the Stanistreet, Smith and Com-
pany, the Indian Medical Record retracted this piece, but the all-pervasive 
collusion of manufacturers, producers, and distributors in various stages 
of adulterating drugs was apparent and raised continual pleas for a food 
and drugs act for India. This was particularly aggravated in the immediate 
postwar era, when British, German, and American companies dumped 
excess World War I stocks on the Indian market on a large scale. In the 
interwar years, therefore, while most problems of adulteration remained 
familiar, they acquired a new urgency in public discourse.
Why was adulteration so pervasive and impossible to contain? One may 
argue that the market itself settled for differing degrees of potency, sold at 
90. Ibid.
91. “Co-operation as Applied to Industrial, Particularly to Pharmaceutical Education,” 
IMR 41 (1921): 79–80.
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correspondingly different rates to suit the pockets of consumers. But the 
medical market (like any other in colonial India) in effect was not laissez-
faire. The MSDs bought a large quantity of medical products (from the 
United Kingdom) and manufactured several drugs in their factories. The 
Indian army and on a lesser priority the government hospitals, therefore, 
were provided with a quality of drugs that usually conformed to the BP 
standard. Until World War I, therefore, the government of India showed 
little interest in controlling the private market in drugs and remained 
indifferent to public opinion or nationalist pressure for a drug control law.
World War I changed government priorities. During the war the Indian 
army was deployed to several places, such as Mesopotamia, where imports 
from Europe proved difficult and those from Germany ceased altogether. 
The MSDs’ own produce proved inadequate; they relied on manufacturers 
based in India to provide several standard drugs and surgical products. 
Several Indian manufacturers, particularly the large producer–retailers, 
made a fortune in supplying government contracts.93
The MSDs ordered from the most prominent British Indian manufac-
turers in Calcutta and Bombay. Nonetheless, during the war, the Indian 
army could no longer remain insulated from the variations in potency of 
medicine and surgical products that pervaded the private market. There 
was one prosecution; the Royal Army Medical Corps put Phillips and 
Company of Bombay on a perpetual blacklist after investigations revealed 
that it had supplied highly adulterated and substandard medicine and 
surgical dressings during the war.94
It was not only that the Indian army had been endangered on the field. 
Most government hospitals and lesser charitable institutions and private 
hospitals faced an acute shortage of medicines in the latter years of the 
war. The clamor for an independence from imports, however qualified, 
resonated even among British medical professionals of the IMS. Here 
the Indian nationalists were joined by others motivated by a huge scar-
city of medicines. The urgency in public discourse reflected that within 
the medical profession itself. Their concern encompassed three related 
themes: the prevention of adulteration of drugs both generic and propri-
etary; professional training for chemists; and an impetus, particularly by 
Indian medical professionals trained in Western medicine as much as by 
Ayurvedas and Hakims, to classify, process, and use Indian substitutes of 
93. Export of quinine to Khartoum, Smith, Stanistreet and Co (May 1919), no. 98, 1, 
National Archives of India, Commerce and Industry, P/9863; Revenue/Commerce and 
Industry, B Proceedings (June 1915), APAC, 137.
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Western imported products as much as possible. With the emphasis on 
import substitution and deeper exploration of indigenous drug plants 
(shorn of their “impurities”) by medical men and entrepreneurs alike, 
the complexity of the market intensified at this time. The huge range of 
indigenous drugs and the local manufacture of drugs came to official 
and medical notice; but public discourse and medical disquiet on the 
lack of regulation in the market grew in the immediate postwar period. 
Indigenous drugs were therefore both sought-after and the objects of sus-
picion. Although the demands for import substitution of drugs from the 
indigenous pharmacopeia continued to inform government policy, once 
the desperate urgency of scarcity was over with the war, there was little 
conviction in any government initiative to introduce import substitution 
through encouraging supplies from Indian manufacturers to the MSDs. 
Several provincial governments (after the provincialization of health in 
1919) did attempt desultory “experiments” with growing other plants such 
as linseed, soya, mustard, ipecacuanha, and cannabis in Sind, Punjab, 
Assam, and the Central Provinces. The results were fragmentary at best.95
After World War I, British, American, and even German imports 
resumed and the short-lived government emphasis on import substitu-
tion dwindled. Large-scale nationalist pressure and a push toward import 
substitution led to some concessions for Indian industry after the war. 
These did not extend to the pharmaceutical industry, however. The MSDs 
continued to control all supplies to government hospitals and imported 
drugs manufactured abroad. Government hospital administrations often 
resented the loss of independence and the red tape involved in their 
sourcing exclusively from the MSDs. In 1935, the surgeon-general of the 
government of Bombay surrendered to pressure from government hos-
pitals to purchase their own medicines through inviting tenders. Several 
British, British Indian, and bazaar companies supplied to the hospitals, 
but this system was discontinued because the surgeon-general ruled that 
the method was liable to fraud. Therefore the MSDs’ control over the 
supply of government hospitals remained intact. This left the private mar-
kets vulnerable to spurious drugs, proprietary medicines that survived on 
aggressive and false advertisement, and adulteration at different levels of 
manufacture and distribution.
As we have seen, the problem of adulteration had aroused public opin-
ion in the early twentieth century. It became prominent in nationalist 
95. National Archives of India, New Delhi, Health Education and Lands Department, 
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discourse during and after the war, when Indian companies alleged that 
foreign companies were dumping substandard goods in the Indian mar-
ket. Nationalists intervened to demand legislation.96 Medical professionals 
both Indian and British Indian showed an interest in import substitution 
as well as the compilation of an Indian Pharmacopeia.
In the interwar period, when the League of Nations initiated inter-
national cooperation on both the control of narcotic drugs and the 
standardization of sera and vaccines, the government capitulated to the 
general clamor at home as well as to the new international initiatives and 
instituted the Drugs Enquiry Committee (DEC) in 1930. It was chaired 
by R. N. Chopra, who had extensively researched the properties of indig-
enous drugs at the Calcutta School of Tropical Medicine. The DEC, which 
consulted the nascent industry, retailers, and medical professionals, made 
several recommendations to regulate the import, sale, and manufacture 
of pharmaceutical products in the country and to streamline the training 
of pharmacists in technical institutes in its report in 1931. The govern-
ment acted on the bulk of these recommendations only when it passed 
the Drug Act in 1944.
Conclusion
Why was the DEC’s report shelved for fifteen years? Barton has argued 
that the transfer of the responsibility for health to provincial governments 
(which, after devolution of power in 1919, was ruled by nationalist govern-
ments) made an all-India policy impossible for the colonial government 
in Delhi.97 Control over the Indian drug industry was a more complicated 
affair than the lack of central government initiatives or a lack of standard-
ization of drugs internationally, although these too played a part. The 
culture of the dispensation of drugs in India necessarily involved manu-
facturer–retailers, bazaar traders, and a multitude of medical professionals 
practicing a range of therapies, allopathic, homeopathic, or Ayurveda or 
Unani, who also sold their own potions and pills to their patients. While 
the Western therapeutic products could be theoretically held to the BP 
standards, Western medical practitioners, British and Indian alike, insisted 
that indigenous drugs could not be standardized because their active prin-
ciples had not been isolated. Many nationalist Western-educated medi-
cal professionals campaigned for an Indian Pharmacopeia, which would 
include the hundreds of drugs, they insisted, that were available in India 
96. Dharamsi Morarji and Company to the Government of India, Indian Medical and 
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and were being exported for processing abroad. Like drug control legisla-
tion, an Indian Pharmacopeia also therefore became a nationalist political 
demand after World War I. At this time the huge and unregulated drug 
market in India continued to flourish and the debates on standardization 
and adulteration were fused; medical practitioners and official authori-
ties claimed that until the active principles of indigenous drugs were all 
identified and “scientifically” tested, it was impossible to bring them (or 
their practitioners) within a regulated market. The demands for import 
substitution of drugs from the indigenous pharmacopeia continued to 
inform government policy, albeit in altogether a too lackadaisical manner 
to invoke any conviction in the policy among consumers. An indigenous 
drugs manufacture committee was formed in 1920, and it diligently 
reported on the progress on manufacture to facilitate import substitution 
until 1923.98 At this time the export trade to India picked up again, and 
import substitution reverted to being a nationalist aspiration rather than 
government policy, until the next world war.
The imported medicines suffered from no such lack of scientific 
authority as the Indian substitutes. Instead, in their case, patent medicines 
remained the crux of public discourse and medical authorities’ consterna-
tion.99 The DEC had condemned the huge trade in patent medicines as 
surviving on aggressive and usually false advertising and on the gullibility 
of medical practitioners as well as consumers, and most of these related to 
imported products. When adulteration became a fiercely contested issue 
between the British Indian distributors and the Indian manufacturers, it 
affected the import trade on two counts. The first was a general, national-
ist push for the consumption of swadeshi goods. Second, the discourse of 
the distinctiveness of the tropics as a unique disease environment (that 
defined tropical medicine) permeated in the popular and even medical 
imagination. This led to the idea that only therapeutics manufactured 
in India were suitable for Indian bodies and the Indian climate.100 While 
this trope was favored by Ayurvedas and Hakims, practitioners of Western 
medicine fused these cultural-climatological ideas within their medical 
practice as well. For instance, Dr. Bose’s Laboratory, a manufacturing 
pharmacy set up in Calcutta by Kartick Chandra Bose, a physician–entre-
preneur, advertised its own products as being superior to imported goods, 
98. Report on the Proceedings of the Drugs Manufacture Committee (Simla: Government Cen-
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because certain drugs (such as lactic acid pills) deteriorated entirely by the 
time they were consumed in “tropical” India.101 Bose also founded a medi-
cal journal, Food and Drugs, in which he advertised his own varied products 
and those of B. K. Paul. Food and Drugs published articles related to the 
beneficial “active components” of Indian fruits and vegetables commonly 
used and available in the bazaars.102 Therefore the issue of adulteration 
was fused with logistic issues of spoilage and climatic and racial tropes and 
was contested fiercely by rival manufacturing and trading firms. While the 
government research institutes continued to produce sera and vaccines 
on a large scale with a focus on their standardization, there was no such 
control over the quality of drugs for sale in the open market. Adulteration 
and its elusive counterpart purity remained contested sites in the medical 
market in colonial India.
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